We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+37.76%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.89B
AUM Growth
+$717M
(+17%)
Cap. Flow
-$266M
Cap. Flow
% of AUM
-5.43%
Top 10 Holdings %
Top 10 Hldgs %
40.48%
Holding
126
New
22
Increased
22
Reduced
35
Closed
16
Top Buys
| 1 |
Pfizer
PFE
|
+$41.7M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$37.3M |
| 3 |
Elevance Health
ELV
|
+$33.5M |
| 4 |
HELP
Cybin Inc
HELP
|
+$24.7M |
| 5 |
Bruker
BRKR
|
+$23.5M |
Top Sells
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$125M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$65.8M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$51.6M |
| 4 |
Axsome Therapeutics
AXSM
|
+$38.9M |
| 5 |
SI-BONE Inc
SIBN
|
+$38M |
Sector Composition
| 1 | Healthcare | 99.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Edgewise Therapeutics
EWTX
$4.25B
| $385M | 7.88% |
15,518,492
| – | – |
|
2
Eli Lilly
LLY
$1.02T
| $324M | 6.62% |
301,200
| – | – |
|
3
Boston Scientific
BSX
$64.4B
| $231M | 4.72% |
2,419,300
-10,000
| -0.4% | -$980K |
|
|
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
| $184M | 3.78% |
2,718,735
| – | – |
|
5
Edwards Lifesciences
EW
$51B
| $157M | 3.22% |
1,842,900
+158,900
| +9% | +$13M |
|
|
UPB
6
Upstream Bio Inc
UPB
$394M
| $155M | 3.16% |
5,693,589
| – | – |
|
7
Intuitive Surgical
ISRG
$138B
| $149M | 3.05% |
263,400
-23,800
| -8% | -$12.7M |
|
|
SION
8
Sionna Therapeutics
SION
$1.94B
| $147M | 3% |
3,561,655
-143,304
| -4% | -$5.43M |
|
|
MBX
9
MBX Biosciences
MBX
$2.77B
| $124M | 2.54% |
3,935,203
-67,684
| -2% | -$1.64M |
|
10
argenx
ARGX
$53.8B
| $123M | 2.51% |
146,000
-26,300
| -15% | -$22.5M |
|
11
Enliven Therapeutics
ELVN
$3.71B
| $123M | 2.51% |
7,959,538
| – | – |
|
12
Alnylam Pharmaceuticals
ALNY
$37.6B
| $115M | 2.35% |
288,800
-12,800
| -4% | -$5.66M |
|
13
Stryker
SYK
$121B
| $114M | 2.34% |
325,000
-34,200
| -10% | -$12.5M |
|
14
ARS Pharmaceuticals
SPRY
$749M
| $96.6M | 1.98% |
8,288,510
| – | – |
|
|
TERN
15
DELISTED
Terns Pharmaceuticals
TERN
| $87M | 1.78% |
2,153,300
-5,409,671
| -72% | -$125M |
|
16
Disc Medicine
IRON
$2.86B
| $84.8M | 1.73% |
1,067,550
-347,470
| -25% | -$29.4M |
|
|
CAI
17
Caris Life Sciences
CAI
$4.86B
| $84.1M | 1.72% |
3,116,011
+81,153
| +3% | +$2.29M |
|
18
Natera
NTRA
$39.3B
| $83.8M | 1.71% |
365,800
-63,500
| -15% | -$13.2M |
|
19
Compass Therapeutics
CMPX
$391M
| $81.7M | 1.67% |
15,219,994
| – | – |
|
20
Structure Therapeutics
GPCR
$3.52B
| $80.8M | 1.65% |
1,161,803
+22,503
| +2% | +$919K |
|
21
Danaher
DHR
$142B
| $68.6M | 1.4% |
299,800
+36,700
| +14% | +$8.07M |
|
22
CG Oncology
CGON
$6.5B
| $63M | 1.29% |
1,516,550
-210,300
| -12% | -$8.7M |
|
|
APLS
23
DELISTED
Apellis Pharmaceuticals
APLS
| $61M | 1.25% |
2,429,868
+106,500
| +5% | +$2.5M |
|
24
ArriVent BioPharma
AVBP
$1.56B
| $60.9M | 1.25% |
3,027,328
| – | – |
|
25
Cigna
CI
$80.1B
| $56.4M | 1.15% |
205,000
+42,200
| +26% | +$11.8M |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM